Biocon Biologics earlier announced a settlement agreement in the United States for a Bmab 1200 launch no later than February 22, 2025
TABRECTA is the brand of Novartis. Natco believes it is the first company to have filed a substantially-complete ANDA
The new Injectable Facility housed in Akums Healthcare started commercial production on 22nd August 2024, with a capacity of 362 million units annually
Sun Pharma has obtained rights from MSD to develop, manufacture and commercialise Tedizolid Phosphate in India
Novartis has option to acquire two future development-ready programs to augment its renal portfolio, a strategic area of focus for the company
Pegfilgrastim is a Pegylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue Filgrastim
Sigachi's entry into the coatings market is strategically timed to capitalize on the industry's growth potential
AGEasy has made significant strides in addressing the pressing health concerns of seniors in India
This product will be manufactured by Indoco at its manufacturing facility located at L-14, Verna Industrial Area, Verna, Goa in India
Subscribe To Our Newsletter & Stay Updated
